'Ecstasy'-induced changes of cerebral glucose metabolism and their correlation to acute psychopathology: An 18-FDG PET study

European Journal of Nuclear Medicine

Volumn 26, Issue 12, 1999, Pages 1572-1579

  Schreckenberger, Mathias ^a   Gouzoulis Mayfrank, Euphrosyne ^a   Sabri, Osama ^a   Arning, Christoph ^a   Zimny, Michael ^a   Zeggel, Thomas ^a   Wagenknecht, Gudrun ^a   Kaiser, Hans Juergen ^a   Sass, Henning ^a   Buell, Udalrich ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Ecstasy; Entactogens; Fluorine 18 deoxyglucose; PET

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; PLACEBO;

ADULT; ARTICLE; BRAIN METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG ABUSE; FEMALE; FRONTAL CORTEX; GLUCOSE METABOLISM; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; MALE; MENTAL DISEASE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL;

3,4-METHYLENEDIOXYAMPHETAMINE; ADULT; CEREBRAL CORTEX; DOUBLE-BLIND METHOD; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; PSYCHOLOGICAL TESTS; RADIOPHARMACEUTICALS;

EID: 0033429037     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050497     Document Type: Article

References (56)

1. 1. Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine. Lancet 1992; 340: 384-387.
2. 2. Ricaurte GA, Martello AL, Katz JL, Martello MB. Lasting effects of MDMA on central serotonergic neurons in non-human primates: neurochemical observations. J Pharmacol Exp Ther 1992; 261: 616-622.
3. 3. Battaglia G, Brooks BP, Kulsakdinum C, DeSouza EB. Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 1988; 149: 159-163.
4. 4. Gouzoulis-Mayfrank E, Hermle L, Kovar KA, Saß H. Die Entaktogene "Ecstasy" (MDMA), "Eve" (MDE) und andere ringsubstituierte Methamphetaminderivate. Nervenarzt 1996; 67: 369-380.
5. 5. Hermle L, Spitzer M, Borchardt D, Kovar KA, Gouzoulis E. Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents? Neuropsychopharmacology 1993; 8: 171-176.
6. 6. Nichols DE. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive drugs 1986; 18: 305-313.
7. 7. Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, et al. Neurometabolic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and D-methamphetamine in healthy volunteers. Neuropsychopharmacology, in press.
8. 8. Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, et al. Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology, in press.
9. 9. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276.
10. 10. Ruoff A. Häufigkeitswörterbuch gesprochener Sprache, Tübingen: and edn. Niemeyer, 1990.
11. 11. Sokoloff L, Reivich M, Kennedy C, et al. The C-14-deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure and normal values in the conscious and anaesthesized albino rat. J Neurochem 1977; 28: 897-916.
12. 12. Phelps HE, Huang SC, Hoffmann EJ, Selin C, Sokoloff L. Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18) 2-fluoro-2-deoxyglucose: validation of a method. Ann Neurol 1979; 6: 371-388.
13. 13. Reivich M, Alavi A, Wolf AP, et al. Glucose metabolic rate kinetic model parameter determination in man: the lumped constant and rate constants for (18-F) fluorodeoxyglucose and (11-C) deoxyglucose. J Cereb Blood Flow Metab 1985; 5: 179-192.
14. 14. Kaiser HJ, Sabri O, Wagenknecht G, et al. A method of correlating and merging cerebral morphology and function by a special head holder. Nuklearmedizin 1994; 33: 123-126.
15. 15. Pietrzyk U, Herholz K, Fink G, et al. An interactive technique for three-dimensional image registration: validation for PET, SPECT, MRI and CT brain studies. J Nucl Med 1994; 35: 2011-2018.
16. 16. Talairach J, Tournoux P. Co-planar stereotactic atlas of the human brain. Stuttgart: Thieme, 1988.
17. 17. Bartlett EJ, Brodie JD, Wolf AP, Christman DR, Laska E, Meissner M. Reproducibility of cerebral glucose metabolic measurements in resting human subjects. J Cereb Blood Flow Metab 1988; 8: 502-512.
18. 18. Maquet P, Dive D, Salmon E, von Frenckel R, Franck G. Reproducibility of cerebral glucose utilization measured by PET and the (18F)-2-fluoro-2-deoxy-D-glucose method in resting, healthy human subjects. Eur J Nucl Med 1990; 16: 267-273.
19. 19. Schreckenberger M, Gouzoulis-Mayfrank E, Sabri O, et al. Cerebral interregional correlations of associative language processing: a PET activation study using 18-FDG. Eur J Nucl Med 1998; 25: 1511-1519.
20. 20. Cohen. Statistical Power Analysis for the Behavioral Sciences, New York: Academic Press, 1977.
21. 21. Bavry JL. STAT-Power. Statistical design analysis system. Scientific Software Inc: 1991.
22. 22. Sabri O, Erkwoh R, Schreckenberger M, et al. Regional cerebral blood flow and negative/positive symptoms in 24 drugnaive schizophrenics. J Nucl Med 1997; 38: 181-188.
23. 23. Sabri O, Erkwoh R, Schreckenberger M, Owega A, Sass H, Buell U. Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in nevertreated schizophrenics. Lancet 1997; 349: 1735-1739.
24. 24. Andreasen NC, O'Leary DS, Cizadlo T, et al. Schizophrenia and cognitive dysmetria: a positron-emission tomography study of dysfunctional prefrontal-thalamic-cerebellar circuitry. Proc Natl Acad Sci 1996; 93: 9985-9990.
25. 25. Biver F, Goldmann S, Delvenne V, et al. Frontal and parietal metabolic disturbances in unipolar depression. Biol Psychiatry 1994; 36: 381-388.
26. 26. Galynker I, Cai J, Ongseng F, Finestone H, Dutta E, Serseni D. Hypofrontality and negative symptoms in major depressive disorder. J Nucl Med 1998; 39: 608-612.
27. 27. Brodie JD, Christman DR, Corona JF, et al. Patterns of metabolic activity in the treatment of schizophrenia. Ann Neurol 1984; 15: 166-169.
28. 28. Lewis SW, Ford RA, Syed GM, Reveley AM, Toone BU. A controlled study of Tc-99m-HMPAO single photon emission imaging in chronic schizophrenia. Psychol Med 1992; 22: 27-35.
29. 29. Wolkin A, Angrist B, Wolf A, et al. Effects of amphetamine on local cerebral metabolism in normal and schizophrenic subjects as determined by positron emission tomography. Psychopharmacology 1987; 92: 241-246.
30. 30. Pearlson GD, Jeffery PJ, Harris GJ, Ross CA, Fischman MW, Camargo EE. Correlation of acute cocaine-induced changes in local cerebral blood flow with subjective effects. Am J Psychiatry 1993; 150: 495-497.
31. 31. London ED, Broussole EPM, Links JM, et al. Morphine-induced metabolic changes in human brain: studies with positron emission tomography and fluorine 18 fluorodeoxyglucose. Arch Gen Psychiatry 1990; 73-81.
32. 32. Wang GJ, Volkow ND, Overall J, et al. Reproducibility of regional brain metabolic responses to lorazepam. J Nucl Med 1996; 37: 1609-1613.
33. 33. Prohovnik I, Arnold SE, Smith G, Lucas LR. Physostigmine reversal of scopolamine-induced hypofrontality. J Cereb Blood Flow Metab 1997; 17: 220-228.
34. 34. Schmahmann JD. Sherman JC. The cerebellar cognitive affective syndrome. Brain 1998; 121: 561-579.
35. 35. Reiman EM, Lane RD, Ahern GL, et al. Neuroanatomical correlates of externally and internally generated human emotion. Am J Psychiatry 1997; 154: 918-925.
36. 36. Allen G, Buxton RB, Wong EC, Courchesne E. Attentional activation of the cerebellum independent of motor involvement. Science 1997; 275: 1940-1943.
37. 37. Barinaga M. The cerebellum: movement coordinator or much more? Science 1996; 272: 482-483.
38. 38. Barker WW, Yoshii F, Loewenstein DA, et al. Cerebrocerebellar relationship during behavioral activation: a PET study. J Cereb Blood Flow Metab 1991; 11: 48-54.
39. 39. Volkow ND, Wang G-J, Fowler JS, et al. Effects of methylphenidate on regional brain glucose metabolism in humans: relationship to dopamine D2 receptors. Am J Psychiatry 1997; 154: 50-55.
40. 18F-2-fluorodeoxyglucose. Psychiatry Res Neuroimaging 1991; 40: 69-78.
41. 41. Volkow ND, Gillespie H, Mullani N, et al. Brain glucose metabolism in chronic marijuhana user at baseline and during marihuana intoxication. Psychiatry Res Neuroimaging 1996; 67: 29-38.
42. 42. Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Staselmann O, Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 1997; 16: 357-372.
43. 43. Petersen SE, Fox PT, Posner MI, Mintun M, Raichle ME. Positron emission tomographic studies of the cortical anatomy of single-word processing. Nature 1988; 331: 585-589.
44. 44. Petersen SE, Fox PT, Posner MI, Mintun M, Raichle ME. Positron emission tomographic studies of the processing of single words. J Cogn Neurosci 1989; 1: 53-170.
45. 45. Posner MI, Petersen SE, Fox PT, Raichle ME. Localization of cognitive operations in the human brain. Science 1988; 240: 1627-1631.
46. 46. Posner MI, Sandson J, Dhawan M, Shulman G. Is word recognition automatic? A cognitive-anatomical approach. J Cogn Neurosci 1989; 1: 50-60.
47. 47. Demonet JF, Wise R, Frackowiak RSJ. Language functions explored in normal subjects by positron emission tomographiy: a critical review. Hum Brain Map 1993; 1: 39-47.
48. 48. Carter CS, Braver TS, Barch DM, Botvinick MM, Noll D, Cohen JD. Anterior cingulate cortex, error detection and the online monitoring of performance. Science 1998; 280: 747-749.
49. 49. Murtha S, Chertkow H, Beauregard M, Dixon R, Evans A. Anticipation causes increased blood flow to the anterior cingulate cortex. Hum. Brain Map 1996; 4: 103-112.
50. 50. Vogt BA, Finch DM, Olson CR. Functional heterogeneity in cingulate cortex: the anterior executive and posterior evaluative regions. Cereb Cortex 1992; 2: 435-443.
51. 51. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997; 42: 85-94.
52. 52. Furmark T, Fischer H, Wik G, Larsson M, Fredrikson M. The amygdala and individual differences in human fear conditioning. Neuroreport 1997; 8: 3957-3860.
53. 53. Angrilli A, Mauri A, Palomba D, et al. Startle reflex and emotion modulation impairment after a right amygdala lesion. Brain 1996; 119: 1991-2000.
54. 54. Zatorre RJ, Evans AC, Meyer E, Gjedde A. Lateralization of phonetic and pitch discrimination in speech processing. Science 1992; 256: 846-849.
55. 55. Paulesu E, Frith CD, Frackowiak RSJ. The neural correlates of the component of working memory. Nature 1993; 362: 342-344.
56. 56. Fiez JA, Raife EA, Balota DA, Schwarz JP, Raichle ME, Petersen SE. A positron emisssion tomography study of the short-term maintenance of verbal information. J Neurosci 1996; 16: 808-822.